AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Amgen reported Q1 2026 revenue of $8.62 billion, up 6% year-over-year, with non-GAAP EPS of $5.15 beating analyst estimates. The company raised full-year 2026 revenue guidance to $37.1B-$38.5B and non-GAAP EPS guidance to $21.70-$23.10, citing strength in 16 brands with double-digit growth.
Key figures
- Eps
- 5.15
- Revenue
- $8.618 billion
- Guidance
- FY26 revenue $37.1B-$38.5B; GAAP EPS $15.62-$17.10; Non-GAAP EPS $21.70-$23.10
- Revenue Yoy
- 6%
- Gaap eps
- 3.34
- Free cash flow
- $1.477 billion
- Operating income gaap
- $2.666 billion
- Operating margin gaap
- 32.4%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.